Trending Now

Nivesh.live

Invest Wisely, Grow Steadily

Menu
Search
Headline
Oil returns to losses as market concerns over trade war persist – CNBC TV18
Oil returns to losses as market concerns over trade war persist – CNBC TV18
US Stock Market Live: Dow futures steady after biggest move since 2008; Japanese stocks up 8%
US Stock Market Live: Dow futures steady after biggest move since 2008; Japanese stocks up 8%
Fed officials worried over stagflation risk ahead of tariffs – CNBC TV18
Fed officials worried over stagflation risk ahead of tariffs – CNBC TV18
Astrome raises million funding, plans to expand wireless and satcom tech offerings – CNBC TV18
Astrome raises $10 million funding, plans to expand wireless and satcom tech offerings – CNBC TV18
‘Nehru became PM’: Amit Shah blames Congress leadership, appeasement politics for partition – CNBC TV18
‘Nehru became PM’: Amit Shah blames Congress leadership, appeasement politics for partition – CNBC TV18
US raises tariffs on China to 125%, announces 90-day ‘pause’ for more than 75 other countries – CNBC TV18
US raises tariffs on China to 125%, announces 90-day ‘pause’ for more than 75 other countries – CNBC TV18
Amazon cancels some inventory orders from China after tariffs – CNBC TV18
Amazon cancels some inventory orders from China after tariffs – CNBC TV18
JSW Energy completes ₹12,468 crore acquisition of 4.7 GW renewable platform from O2 Power – CNBC TV18
JSW Energy completes ₹12,468 crore acquisition of 4.7 GW renewable platform from O2 Power – CNBC TV18
Fintech startup Navadhan secures ₹111 crore Series A funding for geographic and tech expansion – CNBC TV18
Fintech startup Navadhan secures ₹111 crore Series A funding for geographic and tech expansion – CNBC TV18

Tag: Nuvama on Biocon

News
Sarvesh Gautam

Biocon EPS estimates cut by 38% by Nuvama who sees challenges for Sun Pharma, Cipla – CNBC TV18

Brokerage firm Nuvama has cut Biocon Ltd.’s Earnings Per Share (EPS) estimates by 38% for financial year 2025 as it expects struggles for the company’s generics business. A USFDA clearence to the Bengaluru unit, litigation outcome of the Aflibercept, a reinspection of the Malaysia unit and financial deleveraging along with a recovery in Syngene and […]

Back To Top
Translate »